首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1410056

2023年至2028年血友病市場預測

Hemophilia Market - Forecasts from 2023 to 2028

出版日期: 2023年12月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

血友病市場預計將從2021年的111.27億美元成長到2028年的168.19億美元，複合年成長率為6.08%。

血友病是一種罕見疾病，凝血因子缺乏會導致血液凝固異常。結果就是流鼻血、疼痛、水腫、關節緊繃和神祕出血。全球人口中血友病的盛行率不斷上升及其對個人的相關不利影響預計將推動血友病市場的發展。此外，血友病藥物的產品上市、政府的頻繁核准以及優惠政策預計將進一步推動血友病市場的發展。

血友病患病率增加

世界各地血友病病例數量的不斷增加表明了治療的需要，並對血友病市場做出了積極貢獻。例如，根據世界血友病聯合會2021年報告，2021年共有233,577例血友病確診病例，其中A型血友病病例185,318例。根據世界血友病聯盟的數據，自 2020 年以來，盛行率增加了 9%，1999 年至 2021 年間增加了 296%。由於血友病在全球發病率較高，血友病治療藥物的使用將會增加，從而刺激血友病市場的擴大。

血友病的多種副作用

血友病引起的多種併發症顯示需要能夠推動血友病市場的治療方法。內出血會損害組織和器官，甚至可能致命。對於一些患有嚴重血友病的人來說，即使頭部受到輕微的打擊也會導致大腦出血，這是一個嚴重的問題。此外，內出血也會因關節壓力而引起疼痛不適。如果不定期治療內出血，可能會導致關節惡化和關節炎。此外，一些患有嚴重血友病的人對用於治療出血的凝血劑有嚴重的免疫系統反應。在這些情況下，免疫系統會產生阻止凝血因子作用的蛋白質，進而降低藥物的療效。

有利的政府政策

多項努力和政策正在推動血友病市場的發展，包括政府核准血友病治療方法。例如，BioMarin Pharmaceutical 開發的A型血友病基因治療藥物 Roctavian 於 2023 年 6 月獲得 FDA核准。 2023 年 2 月，歐盟委員會核准了uniQure 開發的首個針對成人B型血友病的基因療法。此外，為了改善出血性疾病患者獲得臨床試驗的機會，美國血友病聯合會於 2023 年 6 月宣布了新的工具和搜尋功能。

該領域研究計劃的增加

血友病持續需要增加先進治療的研究計劃和臨床試驗，以推動血友病市場的發展。 2023 年 5 月，輝瑞宣布 Marstacimab 在關鍵的 3 期A型血友病 A和 B 試驗中取得了積極結果。該試驗顯示，與預防性治療和按需靜脈注射治療相比，年出血率顯著降低。此外，2023年3月，美國國家血友病基金會宣布推出治癒之路（P2C），這是一項新的350萬美元風險慈善投資基金，旨在改變包括血友病在內的所有遺傳性血液疾病。）計劃啟動。

市場抑制因素

除了所有促進成長的因素外，預計還會出現限制血友病市場成長的因素。血友病市場預計將因高昂的治療成本和普遍缺乏對新興技術的認知而受到阻礙。基因療法可能提供一種治療血友病的新方法，但價格昂貴，每劑花費 350 萬美元。此外，血友病的基因治療並不總是有效。此外，特定血友病的病因不明是血友病市場的另一個抑制因素，使治療方法開發和測試變得複雜。

北美地區預計將大幅成長

預計在預測期內，北美地區將佔據血友病市場的很大一部分。促成因素包括血友病病例增加、意識提升和技術進步。例如，每 5,000 名男性中就有 1 人患有A型血友病，在美國，每年有 400 名嬰兒出生時患有A型血友病。根據世界血友病聯合會2021的調查顯示，2020年美國有14,816名血友病患者，其中包括A型血友病（11,790例）和B型血友病（30,026例）在內。此外，為了幫助那些無助的血友病患者應對自己的問題，還設立了“全國血友病宣傳月”，這也帶動了該地區的血友病市場。

血友病市場參與者

CSL Behring 是領先的生物製藥公司之一，專注於血漿衍生和重組治療產品。公司產品包括人類凝血因子VIII製劑Biostate（R）、人類凝血因子XII製劑Cluviate（R）、凝血因子XIII製劑Cluvot（R）、凝血因子XIII濃縮物Corifact（R） .我們提供的一些血液製品。諾和諾德成立於 1923 年，總部位於丹麥，是開發嚴重慢性疾病治療方法的領先醫療保健公司之一。該公司正在探索血友病和罕見血液疾病的創新長效皮下治療解決方案，並於 2020 年 2 月推出了A型血友病治療藥物 ESPEROCT®。羅氏 (Roche) 是一家總部位於瑞士的醫療保健公司，成立於 1896 年。該公司開發的治療A型血友病的Hemlibra(R)於2018年獲得美國FDA核准。

新興市場的主要發展

2022 年 5 月，Precision Biologics 經當地衛生當局核准後，在加拿大、歐盟、澳洲和紐西蘭推出了 CRYOcheck 顯色因子 IX 檢測方法。它是為了測量B型血友病患者的 FIX 活性而開發的。 2022年11月，UniQure宣布2023年推出首款B型血友病基因療法Hemgenix，斥資350萬美元。它已獲得美國政府核准，計劃於 2023 年發布。

Hemophilia is a rare disorder in which there are insufficient clotting factors, resulting in improper blood clotting. This results in nosebleeds, pain, edoema, tightness in the joints, and inexplicable bleeding. The growing prevalence of hemophilia among the world population along with its associated adverse effects on individuals is contemplated to boost the hemophilia market. Moreover, the product launches and frequent government approvals for the hemophilia drug along with the favourable policies are further expected to propel the hemophilia market.

Growing Prevalence of Hemophilia Disease

The rising cases of hemophilia worldwide indicate the need for treatment and thus contribute positively to the hemophilia market. For instance, there were 233,577 identified patients with hemophilia in 2021 including 185,318 cases of hemophilia A as per the World Federation of Hemophilia Report 2021. The prevalence rate has increased by 9% from 2020 and 296% between 1999 and 2021 according to the World Federation of Hemophilia. With such a high frequency of hemophilia worldwide, medicines for the condition will be used more frequently, fueling the expansion of the hemophilia market.

Multiple Associated Adverse Effects of Hemophilia

The multiple complications caused by hemophilia indicate the requirement of treatment therapies thereby propelling the hemophilia market. Internal bleeding can injure tissues and organs and is potentially fatal. Some persons with severe hemophilia can experience bleeding into the brain after a minor hit on the head which is a major serious problem. Moreover, internal bleeding may cause agonizing discomfort due to joint pressure. If untreated, internal bleeding regularly can cause joint deterioration or arthritis. Additionally, the immune system reacts badly to the clotting medications used to treat bleeding in some people with severe hemophilia. When this happens, the immune system creates proteins that block the action of the clotting factors, decreasing the efficacy of the medication.

Government Favorable Policies

Several efforts and policies such as approvals by the government in the hemophilia treatment therapies are advancing the hemophilia market. For instance, a gene therapy Roctavian developed by BioMarin Pharmaceutical for hemophilia A was granted approval by the FDA in June 2023. The European Commission approved the first gene therapy in February 2023 for adults with hemophilia B developed by uniQure. Additionally, to improve access to clinical trials for those with bleeding disorders, the Haemophilia Federation of America unveiled a new tool and search function in June 2023.

Rising Research Projects in the Field

The hemophilia disorder is continuously looking for a rise in research projects and clinical trials for advanced treatment thereby propelling the hemophilia market. In May 2023, Pfizer announced the positive Marstacimab results from pivotal phase 3 hemophilia A and B trials. This study showed a significant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimes. Moreover, in March 2023, the National Haemophilia Foundation will launch Pathway to Cures (P2C), a new $3.5 million venture philanthropy investment fund that aims to have a transformative effect on all inheritable blood illnesses, including hemophilia.

Restraints in the Market

Apart from all the growth drivers, some factors are expected to limit the hemophilia market growth. The hemophilia market is anticipated to be hampered by the high cost of therapy and the general lack of awareness of emerging technology. While gene treatments might offer a novel approach to treating hemophilia, they can be expensive, costing up to $3.5 million for a single dose. Additionally, gene treatments for hemophilia aren't always effective. Moreover, the unknown causes of certain hemophilia represent another restraint in the hemophilia market making it complex to develop and experiment with the therapies.

North America is Expected to Grow Significantly

During the forecast period, the North American region is anticipated to account for a sizeable portion of the hemophilia market. Various factors attributed to such a share are rising hemophilia cases, increasing awareness, and technological advancements. For instance, 1 in 5,000 male babies has hemophilia A. Each year, 400 infants are born with hemophilia A in the US. According to the World Federation of Haemophilia 2021 study, there were 14,816 hemophilia patients in the United States in 2020, including those with hemophilia A (11,790 cases) and hemophilia B (30026 cases). Moreover, National Haemophilia Awareness Month was established to raise awareness of the condition and discover solutions to assist hemophiliacs who might feel helpless to deal with their issues during March each year which also boosts the hemophilia market in the region.

Hemophilia Market Players

CSL Behring is one of the leading biopharmaceutical companies focused on plasma-derived and recombination therapeutic products. Biostate® for human coagulation factor VIII, Cluviate® for human coagulation factor XII, Cluvot® for factor XIII, and Corifact® for factor XIII Concentrate are some of the hematology products offered by the company.
Novo Nordisk, founded in 1923 and headquartered in Denmark is one of the leading healthcare companies to develop treatments for serious chronic diseases. The company is exploring innovative long-acting and subcutaneous treatment solutions for hemophilia and rare blood disorders and it launched ESPEROCT® for hemophilia A treatment in February 2020.
Roche is a Switzerland-based healthcare company serving the people since 1896. Hemlibra® developed by the company for the treatment of hemophilia A was granted approval by the US FDA in 2018.

Key Market Developments

In May 2022, Precision Biologic launched the CRYOcheck Chromogenic Factor IX assay in Canada, the EU, Australia, and New Zealand after approval of health authorities in the respective countries. It was developed for the determination of FIX activity in patients with hemophilia B.
In November 2022, UniQure announced the launch of the first hemophilia B gene therapy Hemgenix by 2023 with a price tag of $3.5 million. It is approved by the US government and is expected to launch by 2023.

Segmentation:

By Disease Type

Hemophilia A
Hemophilia B
Others

By Therapy

Replacement Therapy
Gene Therapy
Others (Immune Tolerance Induction Therapy etc.)

By Product Type

Recombinant Coagulation Factor Concentrates
Plasma-derived Coagulation Factor Concentrates
Others (Desmopressin etc.)

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. HEMOPHILIA MARKET BY DISEASE TYPE

5.1. Introduction
5.2. Hemophilia A
5.3. Hemophilia B
5.4. Others

6. HEMOPHILIA MARKET BY THERAPY

6.1. Introduction
6.2. Replacement Therapy
6.3. Gene Therapy
6.4. Others (Immune Tolerance Induction Therapy etc.)

7. HEMOPHILIA MARKET BY PRODUCT TYPE

7.1. Introduction
7.2. Recombinant Coagulation Factor Concentrates
7.3. Plasma-derived Coagulation Factor Concentrates
7.4. Others (Desmopressin etc.)

8. HEMOPHILIA MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others